뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 10 g - oral suspension - 100 mg/ml - active: ciprofloxacin 10 g excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin - oral suspension - 50 mg/ml - active: ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) excipient: hydrochloric acid lactic acid sodium chloride water for injection - infections of the lower respiratory tract. in the treatment of outpatients with pneumonia due to pneumococcus, ciprofloxacin should not be used as a medicine of first choice. ciprofloxacin can be regarded as a suitable treatment for pneumonias caused by klebsiella, enterobacter, proteus, e. coli, pseudomonas, haemophilus, branhamella, legionella, and staphylococcus.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 100 mg/ml - solution for injection - 100 mg/ml - active: cytarabine 100 mg/ml excipient: water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 20 mg/ml - solution for injection - 20 mg/ml - active: cytarabine 20 mg/ml excipient: sodium chloride water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

bayer new zealand limited - omeprazole magnesium 10.3mg equivalent to 10 mg omeprazole;   - enteric coated tablet - 10 mg - active: omeprazole magnesium 10.3mg equivalent to 10 mg omeprazole   excipient: crospovidone ferrous oxide glyceryl monostearate hypromellose methacrylic acid-ethyl acrylate copolymer (1:1) hydroxypropylcellulose iron oxide yellow macrogol 6000 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc sodium hydroxide sodium stearyl fumarate sugar spheres synthetic paraffin titanium dioxide triethyl citrate

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

bayer new zealand limited - omeprazole magnesium 20.6mg equivalent to 20 mg omeprazole;   - enteric coated tablet - 20 mg - active: omeprazole magnesium 20.6mg equivalent to 20 mg omeprazole   excipient: crospovidone ferrous oxide glyceryl monostearate hard paraffin hyprolose hypromellose methacrylic acid-ethyl acrylate copolymer (1:1) macrogol 6000 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc sodium hydroxide sodium stearyl fumarate sugar spheres titanium dioxide triethyl citrate - the short-term relief of reflux-like symptoms in patients aged 18 years and over.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - capecitabine 150mg;   - film coated tablet - 150 mg - active: capecitabine 150mg   excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a14309 - xeloda is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - capecitabine 500mg;   - film coated tablet - 500 mg - active: capecitabine 500mg   excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a14380 - xeloda is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy

오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sinochem international australia pty. ltd. - diflufenican; bromoxynil present as the octanoate; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - diflufenican anilide/aniline-nicotinanilide active 25.0 g/l; bromoxynil present as the octanoate nitrile active 250.0 g/l; n-methyl-2-pyrrolidone solvent other 175.0 g/l; liquid hydrocarbon solvent other 397.0 g/l - herbicide